World Oncology Imaging AI Market Report 2023-2032: Breast and Lung Screening Programs, Complex CT/MRI Staging, PET-based Theranostics, and RT Planning - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "World Market for Oncology Imaging AI, 2023-2032" report has been added to ResearchAndMarkets.com's offering.

Oncology is where medical imaging AI is being tested most aggressively - and where it is starting to stick. Breast and lung screening programs, complex CT/MRI staging, PET-based theranostics, and RT planning are all pushing clinicians toward faster, more consistent, more quantitative imaging decisions.

This report quantifies and explains that shift. It analyzes the World Market for Oncology Imaging AI from 2023 to 2032, using a consistent segmentation across:

• Modality: CT, X-ray/DR (incl. DBT), MRI, PET/Nuclear, Ultrasound
• Tumor site: Breast, Lung/Chest, Prostate, Colorectal, Liver, Neuro-oncology, and others
• Clinical application & pathway stage: from Screening & Risk through Treatment Planning and Response
• Revenue stream & buyer type: Hardware attach, Software, Services, Cloud/PPU across Cancer Centers, IDNs/AMCs, Community providers, and Teleradiology

Beyond the numbers, the report applies the full framework stack - M, ARC-Index, GTM Growth-Maturity, and the new Upgrade & Package Ladders - to show how AI Software vendors, Imaging OEMs, RT planning providers, AI Platforms, Providers/Telerad networks, and Imaging-Pharma/CROs can convert opportunity into repeatable, profitable business.

The goal is not just to describe the market, but to give executives an insights-to-action playbook: where Oncology Imaging AI is truly ready to scale, which clusters will capture the value, and what evidence, packaging, and partnerships will matter most over the next three to five years.

Market Snapshot

Oncology Imaging AI has moved from experimental pilots to a fast scaling market. The report sizes a global opportunity that expands more than 10x between 2023 and 2032, with a compound annual growth rate in the low 30s. North America remains the largest revenue pool over the horizon, but Asia-Pacific is the fastest growing region, overtaking Europe on momentum as national breast and lung programs, domestic OEMs, and cloud first deployments ramp. Europe stays a strong second engine, with adoption paced by MDR, HTA, and national screening strategies.

Most spend concentrates in CT, X ray/DBT and MRI oncology workflows, with PET/Nuclear and Ultrasound forming smaller but high value niches tied to theranostics, quantification, and interventional oncology. The mix of value pools also shifts along the pathway: Detection & Diagnosis remains foundational, but more spend migrates toward screening, treatment planning, and response assessment, where lesion level segmentation, dosimetry, and structured reporting are becoming mandatory for modern cancer programs.

The report quantifies Oncology Imaging AI across regions and countries, modalities, tumor sites, clinical applications, pathway stages, revenue streams, and end use settings (cancer centers, IDNs/AMCs, community providers, teleradiology). Detailed numbers are reserved for report buyers; the public snapshot is directional by design.

What's Covered

• Global market sizing & forecast (2023-2032): total Oncology Imaging AI market today and through 2032, with growth outlook, scenario commentary and key inflection points along the decade.
• Granular segmentation of value pools: analysis by modality, tumor site, clinical application, pathway stage, revenue stream and end-use setting (cancer centers, IDNs/AMCs, community hospitals, imaging centers, teleradiology), aligned with the broader AI-in-Imaging taxonomy.
• Regional & country perspectives: detailed views for North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, including commentary on leading and fast-growth countries, screening initiatives, and local regulatory/reimbursement dynamics.
• Clinical & technology trends across the oncology pathway: how AI is being deployed from breast and lung screening through CT/MR staging, RT planning, PET theranostics and longitudinal response assessment, with use-case mapping to Screening, Diagnosis, Staging, Planning, Response and Surveillance stages.
• Regulatory, reimbursement and evidence landscape (ARC): assessment of Approvals, Reimbursement and Clinical validation by key use case (e.g., DBT AI, CT-lung, adaptive RT, PET response, radiomics), including where Oncology Imaging AI is deployment-ready vs where it remains pilot-only.
• Competitive landscape by cluster: analysis of six major competitive clusters (AI Software, Imaging OEMs, RT/TPS vendors, AI Platforms & Cloud, Providers & Teleradiology, Imaging-Pharma/CRO & Trials), with GTM Growth-Maturity positioning and qualitative company spotlights.
• GTM & packaging strategies: Upgrade & Package Ladders for each cluster (Foundation / Advanced / Elite), recommended commercial and pricing rules, channel and partnership strategies, and implications for attach-rate expansion and suite-based selling.
• Strategic implications & scenarios: cross-cutting insights on where Oncology Imaging AI is likely to become "workflow-critical infrastructure," how APAC's faster growth changes global competition, and what boards, product leaders and investors should prioritize over the next 3-5 years.

Key Topics Covered:

Section 1 Executive Summary

• Why This Market Matters
• Global Growth at a Glance
• Where Along the Pathway the Money Is Moving
• Global Market Drivers and Restraints
• Key Growth Drivers
• Structural Restraints
• Regional Pulse - Who Leads and Who Accelerates
• Five Strategy Headlines to Internalize
• Structural Shifts by Modality, Application, Pathway and End Use
• Competitive Architecture and Vendor Clusters
• Three-Year KPI Outlook and Board-Level Actions
• Actions for Vendors Over the Next 12 Months

Section 2 Research Methodology

• About This Report
• Scope and Segmentation
• Segmentation Axes
• Dual-Lens Architecture
• Top-Down Market Funnel
• Bottom-Up Attach-Rate Flow
• Evidence Confidence
• Framework Stack
• Company Coverage, GTM Growth-Maturity and Competitive Datasets
• Company Universe and Clustering
• GTM Growth-Maturity Quadrants
• Competitive Dataset Tables
• Evidence Confidence
• Upgrade and Package Ladders
• Definitions
• Default Commercial Rules
• Cluster-Based Competitive Architecture and Market Segment Bridging
• Quality Assurance, Limitations and Scenario Handling

Section 3 Strategic Analysis and Frameworks

• AI Software Cluster
• Market Momentum Matrix (AI Software)
• ARC Framework - Oncology Use Cases
• ARC Grid - AI Software
• ARC Index
• Upgrade Ladder Mapping
• Recommendations for AI Software Vendors
• GTM Growth-Maturity Matrix - AI Software Vendors
• Competitive Dataset - AI Software
• Company Scoreboard
• Market Segmentation Bridge
• Upgrade and Package Ladder
• Target Customers and Package Composition
• Recommended Commercial Rules
• Company Spotlights - AI Software Vendors
• Imaging OEMs Cluster
• ARC Framework - OEM Use Cases
• ARC Grid - OEMs
• Competitive Dataset - OEMs
• Scoreboard - OEMs
• Upgrade and Package Ladder - OEMs
• Company Spotlights - OEMs
• RT and Oncology Planning Cluster
• Market Momentum Matrix - RT
• ARC Framework - RT
• Recommendations
• GTM Growth-Maturity Matrix - RT Vendors
• Cluster Bridge and Upgrade Ladder
• Company Spotlights - RT Vendors
• AI Platforms and Cloud Cluster
• ARC Framework - Platforms and Cloud
• Market Momentum Matrix
• Competitive Dataset and Scoreboard
• Upgrade and Package Ladder
• Company Spotlights - Platform Vendors
• Providers and Teleradiology Cluster
• Market Momentum Matrix
• ARC Framework - Providers
• Competitive Dataset and Scoreboard
• Upgrade and Package Ladder
• Company Spotlights - Providers
• Imaging-Pharma and CRO Cluster
• Market Momentum Matrix
• ARC Framework
• Competitive Dataset and Scoreboard
• Upgrade and Package Ladder
• Company Spotlights

Section 4 World Market for Oncology Imaging AI

• Market Overview
• Adoption Drivers
• Regional Growth Snapshot
• Strategic Implications
• Market Momentum and Outlook
• Forecast by Region
• Market by Country End Use
• Market by Modality
• Modality Deep Dives
• Market by Clinical Application
• Application Deep Dives
• Market by Tumor Site
• Tumor Site Deep Dives
• Market by Revenue Stream
• Market by End-Use Organization
• Market by AI Technology
• Market by Pathway Stage
• Regional Mix and Momentum
• Disease-Driven Demand Map
• Workflow Economics
• Pathway Stage Economics

Companies Featured

• 5C Network
• Accuray
• Aidoc
• AIQ Solutions
• Bracco
• Brainlab
• Canon Medical
• CARPL.ai
• deepc (deepcOS)
• DocPanel
• Elekta
• Everlight Radiology
• Ferrum Health
• Fujifilm Healthcare
• GE HealthCare
• Guerbet
• Hologic
• Incepto
• Koios Medical
• Lantheus / EXINI (aPROMISE / PYLARIFY AI)
• Limbus AI
• Lunit
• Median Technologies
• MIM Software
• Mirada Medical
• MVision AI
• Nuance Precision Imaging Network (PIN)
• Philips Healthcare
• Quibim;
• QView Medical
• RadNet / DeepHealth
• RaySearch Laboratories
• Riverain Technologies
• Samsung Healthcare
• ScreenPoint Medical (Transpara)
• Siemens Healthineers
• Teleradiology Solutions
• Tempus (Arterys)
• Therapixel (MammoScreen)
• Unilabs / Telemedicine Clinic (TMC)
• United Imaging
• Vara
• vRad

For more information about this report visit https://www.researchandmarkets.com/r/c0kowu

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.